
Researchers from the University of Cincinnati have found that the drug AM-101 may enhance radiation therapy’s efficacy for lung cancer that has metastasized to the brain. By activating GABA(A) receptors, AM-101 increases autophagy in non-small cell lung cancer (NSCLC) cells, improving radiation sensitivity and patient survival. The drug may also reduce radiation doses, minimizing side effects. The team plans to begin Phase 1 clinical trials to evaluate AM-101's effectiveness in combination with radiation for treating lung cancer.
Like
Save
Share